These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 27729803)

  • 21. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
    Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
    Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
    Ma Y; Wang L; Neitzel LR; Loganathan SN; Tang N; Qin L; Crispi EE; Guo Y; Knapp S; Beauchamp RD; Lee E; Wang J
    Clin Cancer Res; 2017 Apr; 23(8):2027-2037. PubMed ID: 27678457
    [No Abstract]   [Full Text] [Related]  

  • 23. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
    Siu KT; Ramachandran J; Yee AJ; Eda H; Santo L; Panaroni C; Mertz JA; Sims Iii RJ; Cooper MR; Raje N
    Leukemia; 2017 Aug; 31(8):1760-1769. PubMed ID: 27890933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
    Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
    Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma.
    Zhang X; Lee HC; Shirazi F; Baladandayuthapani V; Lin H; Kuiatse I; Wang H; Jones RJ; Berkova Z; Singh RK; Lu J; Qian Y; Raina K; Coleman KG; Crews CM; Li B; Wang H; Hailemichael Y; Thomas SK; Wang Z; Davis RE; Orlowski RZ
    Leukemia; 2018 Oct; 32(10):2224-2239. PubMed ID: 29581547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.
    Tarantelli C; Bernasconi E; Gaudio E; Cascione L; Restelli V; Arribas AJ; Spriano F; Rinaldi A; Mensah AA; Kwee I; Ponzoni M; Zucca E; Carrassa L; Riveiro ME; Rezai K; Stathis A; Cvitkovic E; Bertoni F
    ESMO Open; 2018; 3(6):e000387. PubMed ID: 30305939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
    Kim SR; Lewis JM; Cyrenne BM; Monico PF; Mirza FN; Carlson KR; Foss FM; Girardi M
    Oncotarget; 2018 Jun; 9(49):29193-29207. PubMed ID: 30018745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-canonical transcriptional consequences of BET inhibition in cancer.
    Letson C; Padron E
    Pharmacol Res; 2019 Dec; 150():104508. PubMed ID: 31698067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoiesis provides a BRD's eye view of BET protein function.
    Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
    Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insights into novel emerging epigenetic drugs in myeloid malignancies.
    Chandhok NS; Prebet T
    Ther Adv Hematol; 2019; 10():2040620719866081. PubMed ID: 31431820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases.
    Wu D; Duan Q
    Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BET bromodomain inhibitors synergize with ATR inhibitors in melanoma.
    Muralidharan SV; Einarsdottir BO; Bhadury J; Lindberg MF; Wu J; Campeau E; Bagge RO; Stierner U; Ny L; Nilsson LM; Nilsson JA
    Cell Death Dis; 2017 Aug; 8(8):e2982. PubMed ID: 28796244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
    Albrecht BK; Gehling VS; Hewitt MC; Vaswani RG; Côté A; Leblanc Y; Nasveschuk CG; Bellon S; Bergeron L; Campbell R; Cantone N; Cooper MR; Cummings RT; Jayaram H; Joshi S; Mertz JA; Neiss A; Normant E; O'Meara M; Pardo E; Poy F; Sandy P; Supko J; Sims RJ; Harmange JC; Taylor AM; Audia JE
    J Med Chem; 2016 Feb; 59(4):1330-9. PubMed ID: 26815195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
    Dai X; Gan W; Li X; Wang S; Zhang W; Huang L; Liu S; Zhong Q; Guo J; Zhang J; Chen T; Shimizu K; Beca F; Blattner M; Vasudevan D; Buckley DL; Qi J; Buser L; Liu P; Inuzuka H; Beck AH; Wang L; Wild PJ; Garraway LA; Rubin MA; Barbieri CE; Wong KK; Muthuswamy SK; Huang J; Chen Y; Bradner JE; Wei W
    Nat Med; 2017 Sep; 23(9):1063-1071. PubMed ID: 28805820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BET Inhibitors as Anticancer Agents: A Patent Review.
    Ali I; Choi G; Lee K
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):340-364. PubMed ID: 28786345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc-induced lymphoma cells.
    Muralidharan SV; Bhadury J; Nilsson LM; Green LC; McLure KG; Nilsson JA
    Oncogene; 2016 Sep; 35(36):4689-97. PubMed ID: 26804177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.